<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ciltacabtagene autoleucel: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ciltacabtagene autoleucel: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ciltacabtagene autoleucel: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="135148" href="/d/html/135148.html" rel="external">see "Ciltacabtagene autoleucel: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F58885564"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">CAR T Cell Immunotherapies Safety Alert</span>
<span class="collapsible-date">November 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has received reports of T-cell malignancies in patients treated with BCMA-directed or CD19-directed autologous CAR T cell immunotherapies. Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, the FDA is investigating the identified risk of T-cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action.</p>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fsafety%2Fmedical-product-safety-information%2Fbcma-directed-or-cd19-directed-autologous-chimeric-antigen-receptor-car-t-cell-immunotherapies-fda&amp;token=CPonYRqdfrFjx6CKP0vl9LTob0cqcI3qUBXtP3MLAWgM%2BD1zl3Y7ExxC1eaqryzRwVwEeE1tZcbB2EssFe3J5INYh0xC%2F0czCFPh01uuP3j57o9U2wIVHF64GZGktjs%2FGaSKvb%2BOqEvaPFn4oy6TACd%2FL5P8o8JrW4tTWtHrxrQ%3D&amp;TOPIC_ID=135088" target="_blank">https://www.fda.gov/safety/medical-product-safety-information/bcma-directed-or-cd19-directed-autologous-chimeric-antigen-receptor-car-t-cell-immunotherapies-fda</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F56628725"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cytokine release syndrome:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Cytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred in patients following treatment with ciltacabtagene autoleucel. Do not administer ciltacabtagene autoleucel to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurologic toxicities:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Immune effector cell-associated neurotoxicity syndrome (ICANS), which may be fatal or life-threatening, occurred following treatment with ciltacabtagene autoleucel, including before CRS onset, concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with ciltacabtagene autoleucel. Provide supportive care and/or corticosteroids as needed.</p>
<p style="text-indent:0em;margin-left:2em;">Parkinsonism and Guillain-Barr√© syndrome and their associated complications resulting in fatal or life-threatening reactions have occurred following treatment with ciltacabtagene autoleucel.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hemophagocytic lymphohistiocytosis/macrophage activation syndrome:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment with ciltacabtagene autoleucel. HLH/MAS can occur with CRS or neurologic toxicities.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Prolonged and recurrent cytopenia:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Prolonged and/or recurrent cytopenias with bleeding and infection and requirement for stem cell transplantation for hematopoietic recovery occurred following treatment with ciltacabtagene autoleucel.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Secondary hematological malignancies:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Secondary hematological malignancies, including myelodysplastic syndrome and acute myeloid leukemia, have occurred in patients following treatment with ciltacabtagene autoleucel.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk Evaluation and Mitigation Strategy (REMS):</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Ciltacabtagene autoleucel is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the CARVYKTI REMS Program.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56641708"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Carvykti</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F56628731"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-BCMA;</li>
<li>
                        Antineoplastic Agent, CAR-T Immunotherapy;</li>
<li>
                        CAR-T Cell Immunotherapy;</li>
<li>
                        Cellular Immunotherapy, Autologous;</li>
<li>
                        Chimeric Antigen Receptor T-Cell Immunotherapy</li></ul></div>
<div class="block doa drugH1Div" id="F56656345"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage</b>
<b> guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: For autologous use only. Confirm patient identity matches cassette and infusion bag prior to infusion. </b>Confirm availability of autologous ciltacabtagene autoleucel prior to initiating lymphodepleting chemotherapy. Confirm that tocilizumab and emergency equipment are available prior to ciltacabtagene autoleucel infusion and during recovery period. Premedicate with acetaminophen 650 to 1,000 mg IV or orally and diphenhydramine 25 to 50 mg IV or orally (or other H<sub>1</sub> antihistamine) ~30 to 60 minutes prior to ciltacabtagene autoleucel infusion. Avoid prophylactic dexamethasone or other systemic corticosteroids, as they may interfere with ciltacabtagene autoleucel activity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> A treatment course consists of 1) lymphodepleting chemotherapy (with fludarabine and cyclophosphamide) for 3 days, and 2) ciltacabtagene autoleucel infusion 2 to 4 days after completion of lymphodepleting chemotherapy. Administer prophylactic antimicrobials as clinically indicated for up to 6 months (or longer) according to standard institutional guidelines or consistent with post American Society for Transplantation and Cellular Therapy consensus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35210399']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35210399'])">Ref</a></span>). Consider antiviral therapy to prevent viral reactivation as appropriate. Counsel patients on infection prevention measures and follow institution protocols for vaccination and management of immunocompromised patients with COVID-19.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Lymphodepleting chemotherapy: </i>Delay lymphodepleting regimen for unresolved serious adverse events (eg, clinically significant active infection, cardiac toxicity, pulmonary toxicity) from preceding bridging therapies or active graft-versus-host disease from prior allogeneic hematopoietic cell transplant. Consider repeating lymphodepleting regimen if ciltacabtagene autoleucel infusion is delayed by &gt;14 days and patient has fully recovered from initial lymphodepleting regimen. Refer to product labeling for further information.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ac522d92-c8b2-419c-959b-57ffc7ab0312">Multiple myeloma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, relapsed or refractory:</b>
<b>Note:</b> Delay ciltacabtagene autoleucel for clinically significant active infection or inflammatory disorders or for ‚â• grade 3 nonhematologic toxicity due to lymphodepleting chemotherapy (excluding grade 3 nausea, vomiting, diarrhea, or constipation) until recovered to ‚â§ grade 1.</p>
<p style="text-indent:-2em;margin-left:4em;">Target dose range: <b>IV:</b> 0.5 to 1 √ó 10<sup>6</sup> chimeric antigen receptor (CAR)-positive viable T cells per kg of body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34175021','lexi-content-ref-35658469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34175021','lexi-content-ref-35658469'])">Ref</a></span>); maximum dose: 1 √ó 10<sup>8</sup> CAR-positive viable T cells per single infusion.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56656347"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ‚â•60 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, mild kidney impairment did not impact ciltacabtagene autoleucel pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;60 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F56656348"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (total bilirubin ‚â§ ULN and AST &gt; ULN, or total bilirubin &gt;1 to ‚â§1.5 √ó ULN, or AST &gt; ULN): There are no dosage adjustments provided in the manufacturer's labeling; however, mild impairment did not impact ciltacabtagene autoleucel pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate or severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dot drugH1Div" id="F56656387"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytokine release syndrome: </b>Monitor for cytokine release syndrome (CRS); if fever, hypoxia, and hypotension occur, evaluate for other causes, and manage as appropriate. If CRS is suspected, manage according to the CRS table at the first sign of CRS. If CRS occurs, monitor closely for cardiac and other organ function abnormalities until resolution of symptoms; consider antiseizure prophylaxis with levetiracetam. Monitor patients with ‚â• grade 2 CRS (eg, hypotension unresponsive to fluids or hypoxia requiring supplemental oxygen) with continuous cardiac telemetry and pulse oximetry. Consider intensive care monitoring and supportive therapy for severe or life-threatening CRS.</p>
<p style="text-indent:-2em;margin-left:4em;">Consider alternate treatment options (eg, higher corticosteroid dose, alternative anticytokine agents, anti‚ÄìT-cell therapies) for CRS refractory to first-line interventions (tocilizumab or tocilizumab and corticosteroids). Refractory CRS is characterized by fevers, end-organ toxicity (eg, hypoxia, hypotension) not improving within 12 hours of first-line interventions, or development of hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).</p>
<p style="text-indent:-2em;margin-left:4em;">If concurrent neurologic toxicity is suspected during CRS, administer more aggressive corticosteroid intervention (based on the CRS and neurotoxicity tables), tocilizumab (according to the CRS table), and antiseizure mediations (according to the neurotoxicity table).</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Ciltacabtagene Autol</b>
<b>eucel-Related CRS Grading and Management</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>CRS grade</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Tocilizumab<sup>a</sup></b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Corticosteroids<sup>b</sup></b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Also see tocilizumab monograph.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> If corticosteroids are initiated, continue corticosteroids until ‚â§ grade 1; taper corticosteroids if total corticosteroid exposure is &gt;3 days.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Attributed to CRS. Fever may not always be present concurrently with hypotension or hypoxia (may be masked by antipyretics and/or anticytokine therapy, such as tocilizumab or steroids). The absence of fever does not impact CRS management; CRS management is driven by hypotension and/or hypoxia and by the more severe symptom not attributable to any other cause.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>d<sub></sub></sup>Low-flow nasal cannula is ‚â§6 L/min; high-flow nasal cannula is &gt;6 L/min.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>e<sub></sub></sup>For unresponsive CRS, monoclonal antibodies that target cytokines may be considered (based on institutional practice).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 1: Temperature ‚â•38¬∞C (100.4¬∞F)<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">If onset is &lt;72 hours after cell infusion, consider tocilizumab 8 mg/kg (maximum dose: 800 mg) IV over 1 hour.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">‚Äì</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Grade 2: Symptoms require and respond to moderate intervention.</p>
<p style="text-indent:0em;text-align:left;">Temperature ‚â•38¬∞C (100.4¬∞F)<sup>c</sup> with:</p>
<p style="text-indent:0em;text-align:left;">Hypotension not requiring vasopressors, <b>and/or</b></p>
<p style="text-indent:0em;text-align:left;">Hypoxia requiring oxygen via canula<sup>d</sup> or blow by, <b>or </b></p>
<p style="text-indent:0em;text-align:left;">Grade 2 organ toxicity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Administer tocilizumab 8 mg/kg (maximum dose: 800 mg) IV over 1 hour. Repeat tocilizumab every 8 hours, as needed, if not responsive to IV fluids up to 1 L or increasing supplemental oxygen.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Consider dexamethasone 10 mg IV every 12 to 24 hours.</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">If no improvement within 24 hours or rapid progression, repeat tocilizumab and escalate dexamethasone to 20 mg IV every 6 to 12 hours.</p>
<p style="text-indent:0em;text-align:center;">If no improvement within 24 hours or continued rapid progression, switch to methylprednisolone 2 mg/kg IV every 12 hours.</p>
<p style="text-indent:0em;text-align:center;">After 2 tocilizumab doses, consider alternative anticytokine agents<sup>e</sup>.</p>
<p style="text-indent:0em;text-align:center;">Do not exceed 3 tocilizumab doses per 24 hours, and maximum total of 4 tocilizumab doses.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Grade 3: Symptoms require and respond to aggressive intervention.</p>
<p style="text-indent:0em;text-align:left;">Temperature ‚â•38¬∞C (100.4¬∞F)<sup>c</sup> with:</p>
<p style="text-indent:0em;text-align:left;">Hypotension requiring one vasopressor ¬± vasopressin, <b>and/or</b></p>
<p style="text-indent:0em;text-align:left;">Hypoxia requiring oxygen via high-flow nasal canula<sup>d</sup>, face mask, non-rebreather mask, or Venturi mask, <b>or </b></p>
<p style="text-indent:0em;text-align:left;">Grade 3 organ toxicity or grade 4 transaminitis.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Manage per grade 2.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Administer dexamethasone 10 mg IV every 12 hours.</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">If no improvement within 24 hours or rapid CRS progression, repeat tocilizumab and escalate dexamethasone to 20 mg IV every 6 to 12 hours.</p>
<p style="text-indent:0em;text-align:center;">If no improvement within 24 hours or continued rapid progression, switch to methylprednisolone 2 mg/kg IV every 12 hours.</p>
<p style="text-indent:0em;text-align:center;">After 2 tocilizumab doses, consider alternative anticytokine agents<sup>e</sup>.</p>
<p style="text-indent:0em;text-align:center;">Do not exceed 3 tocilizumab doses per 24 hours, and maximum total of 4 tocilizumab doses.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Grade 4: Life-threatening symptoms. Requires ventilator support, CVVHD.</p>
<p style="text-indent:0em;text-align:left;">Temperature ‚â•38¬∞C (100.4¬∞F)<sup>c</sup> with:</p>
<p style="text-indent:0em;text-align:left;">Hypotension requiring multiple vasopressor (excluding vasopressin), <b>and/or</b></p>
<p style="text-indent:0em;text-align:left;">Hypoxia requiring oxygen positive pressure (eg, CPAP, BiPAP, intubation, and mechanical ventilation), <b>or </b></p>
<p style="text-indent:0em;text-align:left;">Grade 4 organ toxicity (excluding transaminitis)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Manage per grade 2.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Administer dexamethasone 20 mg IV every 6 hours.</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">After 2 tocilizumab doses, consider alternative anticytokine agents<sup>e</sup>.</p>
<p style="text-indent:0em;text-align:center;">Do not exceed 3 tocilizumab doses per 24 hours, and maximum total of 4 tocilizumab doses.</p>
<p style="text-indent:0em;text-align:center;">If no improvement within 24 hours, consider methylprednisolone (1 to 2 g IV, repeat every 24 hours, if needed; taper as clinically indicated) or other immunosuppressants (eg, other anti‚ÄìT-cell therapies).</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurotoxicity:</b> Monitor for signs/symptoms of neurologic toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) and other neurotoxicities. Rule out other causes of neurologic signs/symptoms. Provide intensive care and supportive therapy for severe or life-threatening neurologic toxicities. If ICANS is suspected, manage according to the neurotoxicity table. If concurrent CRS is suspected during neurotoxicity, administer more aggressive corticosteroid intervention (based on the CRS and neurotoxicity tables), tocilizumab (according to the CRS table), and antiseizure mediations (according to the neurotoxicity table). ICANS grading/management is determined by the most severe event (ICE [immune effector cell-associated encephalopathy] score, level of consciousness, seizure, motor findings, raised intracranial pressure ([ICP]/cerebral edema) that is not attributable to any other cause.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Ciltacabtagene Autoleucel-Related Neurotoxicity (ICANS) Grading and Management</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Neurotoxicity (ICANS) grade</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Corticosteroids and antiseizure medication</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Dexamethasone or dexamethasone equivalent.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup></sup>
<sup>b </sup>If patient is arousable and able to perform ICE assessment, assess:</p>
<ul>
<li>
<p style="text-indent:0em;">Orientation (oriented to year, month, city, hospital = 4 points)</p></li>
<li>
<p style="text-indent:0em;">Naming (name 3 objects, [eg, point to clock, pen, button = 3 points])</p></li>
<li>
<p style="text-indent:0em;">Follows commands (eg, ‚Äúshow me 2 fingers‚Äù or ‚Äúclose your eyes and stick out your tongue‚Äù = 1 point)</p></li>
<li>
<p style="text-indent:0em;">Writing (ability to write a standard sentence = 1 point)</p></li>
<li>
<p style="text-indent:0em;">Attention (count backwards from 100 by ten = 1 point)</p></li></ul>
<p style="text-indent:0em;text-align:left;">If patient is unarousable and unable to perform ICE assessment (Grade 4 ICANS) = 0 points.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Intracranial hemorrhage ¬± associated edema is not considered a neurotoxicity feature and is excluded from ICANS grading.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>Tremors and myoclonus associated with immune effector cell therapies may be graded; however, they do not influence ICANS grading.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 1</p>
<p style="text-indent:0em;text-align:left;">ICE score 7 to 9<sup>b </sup></p>
<p style="text-indent:0em;text-align:left;">
<b>or</b></p>
<p style="text-indent:0em;text-align:left;">Depressed level of consciousness; awakens spontaneously</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">Consider dexamethasone<sup>a</sup> 10 mg IV every 12 to 24 hours for 2 to 3 days.</p>
<p style="text-indent:0em;text-align:center;">Consider nonsedating antiseizure medications (eg, levetiracetam) for seizure prophylaxis.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2</p>
<p style="text-indent:0em;text-align:left;">ICE score 3 to 6<sup>b </sup></p>
<p style="text-indent:0em;text-align:left;">
<b>or</b></p>
<p style="text-indent:0em;text-align:left;">Depressed level of consciousness; awakens to voice</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">Initiate dexamethasone<sup>a</sup> 10 mg IV every 12 hours for 2 to 3 days (or longer for persistent symptoms). Consider corticosteroid taper if total corticosteroid exposure is &gt;3 days.</p>
<p style="text-indent:0em;text-align:center;">If no improvement after 24 hours or worsening of neurologic toxicity, increase dexamethasone<sup>a</sup> dose and/or frequency up to a maximum of 20 mg IV every 6 hours.</p>
<p style="text-indent:0em;text-align:center;">Consider nonsedating antiseizure medications (eg, levetiracetam) for seizure prophylaxis.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3</p>
<p style="text-indent:0em;text-align:left;">ICE score 0 to 2<sup>b </sup>(if ICE score is 0, but the patient is arousable [eg, awake with global aphasia] and able to perform assessment)</p>
<p style="text-indent:0em;text-align:left;">
<b>or</b></p>
<p style="text-indent:0em;text-align:left;">Depressed level of consciousness; awakens only to tactile stimulus</p>
<p style="text-indent:0em;text-align:left;">
<b>or</b></p>
<p style="text-indent:0em;text-align:left;">Seizures (any clinical seizure, focal or generalized, that resolves rapidly, <b>or</b> nonconvulsive seizures on EEG that resolve with intervention)</p>
<p style="text-indent:0em;text-align:left;">
<b>or</b></p>
<p style="text-indent:0em;text-align:left;">Raised ICP: Focal/local edema on neuroimaging<sup>c</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">Initiate dexamethasone<sup>a</sup> 10 to 20 mg IV every 6 hours.</p>
<p style="text-indent:0em;text-align:center;">If no improvement after 24 hours, or worsening neurologic toxicity, escalate dexamethasone<sup>a</sup> dose to at least 20 mg IV every 6 hours <b>or</b> escalate to high-dose methylprednisolone (1 to 2 g/day, repeat every 24 hours if needed; taper as clinically indicated).</p>
<p style="text-indent:0em;text-align:center;">Consider non-sedating antiseizure medications (eg, levetiracetam) for seizure prophylaxis.</p>
<p style="text-indent:0em;text-align:center;">If cerebral edema is suspected, consider hyperventilation and hyperosmolar therapy. Administer methylprednisolone 1 to 2 g IV, repeat every 24 hours, if needed; taper as clinically indicated.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4</p>
<p style="text-indent:0em;text-align:left;">ICE score 0<sup>b </sup></p>
<p style="text-indent:0em;text-align:left;">
<b>or</b></p>
<p style="text-indent:0em;text-align:left;">Depressed level of consciousness; either patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse, <b>or</b> stupor or coma</p>
<p style="text-indent:0em;text-align:left;">
<b>or</b></p>
<p style="text-indent:0em;text-align:left;">Seizures (life-threatening prolonged seizure [&gt;5 minutes], or repetitive clinical or electrical seizures without return to baseline in between)</p>
<p style="text-indent:0em;text-align:left;">
<b>or</b></p>
<p style="text-indent:0em;text-align:left;">Motor findings<sup>d</sup> (deep focal motor weakness, such as hemiparesis or paraparesis)</p>
<p style="text-indent:0em;text-align:left;">
<b>or</b></p>
<p style="text-indent:0em;text-align:left;">Raised ICP/cerebral edema, with signs/symptoms, such as: diffuse cerebral edema on neuroimaging, decerebrate or decorticate posturing, cranial nerve VI palsy, papilledema, or Cushing‚Äôs triad</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">Initiate dexamethasone<sup>a</sup> 20 mg IV every 6 hours.</p>
<p style="text-indent:0em;text-align:center;">If no improvement after 24 hours, or worsening neurologic toxicity, escalate to high-dose methylprednisolone (1 to 2 g IV per day, repeat every 24 hours, if needed; taper as clinically indicated).</p>
<p style="text-indent:0em;text-align:center;">Consider nonsedating antiseizure medications (eg, levetiracetam) for seizure prophylaxis.</p>
<p style="text-indent:0em;text-align:center;">If raised ICP/cerebral edema is suspected, consider hyperventilation and hyperosmolar therapy. Administer high-dose methylprednisolone (1 to 2 g IV per day, repeat every 24 hours, if needed; taper as clinically indicated). Consider neurology and/or neurosurgery consultation.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Other toxicities: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Cranial nerve palsies: Consider management with systemic corticosteroids (depending on the severity and progression of signs/symptoms).</p>
<p style="text-indent:-2em;margin-left:4em;">Cytopenias: Manage cytopenia with growth factor and blood product transfusion support (according to local institutional guidelines).</p>
<p style="text-indent:-2em;margin-left:4em;">Guillain-Barr√© syndrome: Consider treatment with supportive care measures and in conjunction with IV immunoglobulin and plasma exchange (depending on the severity).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemophagocytic lymphohistiocytosis/macrophage activation syndrome: Manage per institutional standards (which may include transfusion).</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Manage promptly and appropriately based on the severity of the hypersensitivity reaction.</p>
<p style="text-indent:-2em;margin-left:4em;">Hypogammaglobulinemia (IgG &lt;400 mg/dL): Administer IV immune globulin and manage as indicated per local institutional guidelines, including infection precautions and antibiotic and/or antiviral prophylaxis.</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Administer prophylactic, preemptive, and/or therapeutic antimicrobials according to standard institutional guidelines. If infection occurs, manage appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">Neutropenic fever: Evaluate for infection, and manage with broad-spectrum antibiotics, fluids, and other supportive care, as clinically indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">Parkinsonism: Manage with supportive care measures.</p></div>
<div class="block doe drugH1Div" id="F56656346"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F56638803"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (23%), hypertension (19%), hypotension (51%), tachycardia (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (22%), decreased appetite (29%), diarrhea (33%; grades ‚â•3: 1%), nausea (31%; grades ‚â•3: 1%), vomiting (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (grades 3/4: 72%), disorder of hemostatic components of blood (22%; grades ‚â•3: 2%; including disseminated intravascular coagulation, hypofibrinogenemia, increased INR, prolonged partial thromboplastin time, prolonged prothrombin time), hemorrhage (15%; grades ‚â•3: 4%), hypogammaglobulinemia (94%; grades ‚â•3: 2%), lymphocytopenia (grades 3/4: 99%), neutropenia (grades 3/4: 98%), thrombocytopenia (grades 3/4: 63%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (grades 3/4: 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Cytokine release syndrome (95%; serious: 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (41% to 59%; including bacterial infection [10%], fungal infection [grades 3/4: 1%], viral infection [23%])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (33%), dizziness (23%), encephalopathy (30%), fatigue (47%), headache (27%), insomnia (13%), motor dysfunction (16%), neurotoxicity (26%; including cranial nerve palsy [3%], Guillain-Barre syndrome, Immune Effector Cell-associated Neurotoxicity Syndrome [ICANS: 23%], myelitis [immune mediated], parkinsonism [4%], peripheral neuropathy [6%; grade 3: 2%])</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (48%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (39%), dyspnea (23%), hypoxia (12%), nasal congestion (15%), pneumonia (12%), upper respiratory tract infection (28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (96%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (8%), chest pain (7%), thrombosis (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysphagia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (10%; grades ‚â•3: 10%), hemophagocytic lymphohistiocytosis (including macrophage activation syndrome: 1%), tumor lysis syndrome (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aphasia (8%), ataxia (8%), cerebrovascular accident (1%), cogwheel rigidity (1%), delirium (5%), depression (4%), falling (3%), mask-like face (3%), paresis (1%), psychomotor impairment (1%), seizure (1%), speech disturbance (low speech: 1%), tremor (6%), writing difficulty (3%; micrographia: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Abnormal posture (1%), bradykinesia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia (1%), nystagmus disorder (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoalbuminemia, hypocalcemia, hypokalemia, hyponatremia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hematologic &amp; oncologic: Hematologic malignancy (T-cell) (FDA Safety Communication 2023)</p></div>
<div class="block coi drugH1Div" id="F56628727"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F56656131"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Cytokine release syndrome: Cytokine release syndrome (CRS), including fatal or life-threatening reactions, commonly occurred with ciltacabtagene autoleucel; grade 3 or higher CRS has occurred. The median time to onset of CRS was 7 days (range: 1 to 12 days) and the median duration was 4 days (range:1 to 40 days), although there was a case report of a CRS duration of 97 days (with a subsequent fatal outcome). In patients who experienced CRS, the most common manifestations included fever, chills, hypotension, increased AST or ALT, and/or sinus tachycardia. Grade 3 or higher events associated with CRS included increased AST and ALT, hyperbilirubinemia, hypotension, fever, hypoxia, respiratory failure, acute kidney injury, disseminated intravascular coagulation and hemorrhage, hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS), angina pectoris, supraventricular and ventricular tachycardia, malaise, myalgias, and increased C-reactive protein, ferritin, blood alkaline phosphatase, and gamma-glutamyl transferase. CRS has been reported to be associated with findings of HLH/MAS (the physiology of the syndromes may overlap). Fatal retroperitoneal hemorrhage in a patient with CRS and suspected HLH/MAS in the setting of thrombocytopenia, coagulopathy, and anticoagulation has been observed. Patients should seek immediate medical attention if signs/symptoms of CRS occur at any time.</p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Cytopenias: Prolonged and/or recurrent cytopenias with bleeding, infection, and/or requirement for hematopoietic cell transplantation for hematopoietic recovery have occurred following lymphodepleting chemotherapy and ciltacabtagene autoleucel. Prolonged (unresolved by day 30 after ciltacabtagene autoleucel infusion) grade 3 or 4 neutropenia and thrombocytopenia have been reported. Of patients recovering from grade 3 or 4 neutropenia after 1 month, the median time to recovery from ciltacabtagene autoleucel infusion was 1.8 months (range: 1 to ~4 months); of those recovering from grade 3 or 4 thrombocytopenia after 1 month, the median time to recovery from ciltacabtagene autoleucel infusion was 1.9 months (range: ~1 to 8.5 months). One patient required autologous hematopoietic cell therapy for hematopoietic reconstitution due to prolonged thrombocytopenia. Recurrent grade 3 or 4 neutropenia, thrombocytopenia, lymphopenia, and anemia were observed after recovery from initial grade 3 or 4 cytopenias. After day 60 following ciltacabtagene autoleucel, some patients experienced recurrent grade 3 or higher lymphopenia, neutropenia, and thrombocytopenia after initial recovery.</p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Hemophagocytic lymphohistiocytosis/macrophage activation syndrome: HLH/MAS, including a fatal case, has been observed with ciltacabtagene autoleucel. HLH is a life-threatening condition with a high mortality rate if not recognized and managed early. Manifestations of HLH/MAS include hypotension, hypoxia with diffuse alveolar damage, coagulopathy, cytopenia, and multi-organ dysfunction, including kidney dysfunction. HLH/MAS is associated with an increased risk of severe bleeding. Fatal intracerebral and GI hemorrhage in the setting of coagulopathy and thrombocytopenia in a patient with grade 4 HLH/MAS occurred 12 days following ciltacabtagene autoleucel treatment. HLH/MAS can occur with CRS or neurologic toxicities.</p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Hypersensitivity: Hypersensitivity reactions have occurred following ciltacabtagene autoleucel infusion. Reactions were mild and symptoms included flushing, chest discomfort, tachycardia, wheezing, tremor, and burning sensation. Serious hypersensitivity reactions, including anaphylaxis, may be due to the dimethyl sulfoxide (DMSO) in ciltacabtagene autoleucel.</p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Hypogammaglobulinemia: Hypogammaglobulinemia can occur with ciltacabtagene autoleucel. IgG levels fell below 500 mg/dL in a majority of patients. Some patients required IV immunoglobulin following ciltacabtagene autoleucel, for either management of an adverse reaction or for prophylaxis.</p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Infections: Severe, life-threatening, or fatal infections have occurred with ciltacabtagene autoleucel, including viral, bacterial, and fungal infections, as well as unspecified pathogens. Neutropenic fever has been reported; may be concurrent with CRS. Hepatitis B virus reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients with hypogammaglobulinemia. Increased rates of fatal COVID-19 infections have been reported in patients with multiple myeloma who received ciltacabtagene autoleucel; follow guidelines for immunization and management of immunocompromised patients with COVID-19 and counsel patients in the importance of infection prevention. Other fatal infections included bronchopulmonary aspergillosis, <i>Pneumocystis jirovecii</i> pneumonia, cytomegalovirus colitis (with HSV-1 hepatitis), and mycotic aneurism (due to cerebral aspergillosis).</p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Myelitis: Grade 3 immune-mediated myelitis has occurred 25 days following ciltacabtagene autoleucel treatment. Symptoms included hypoesthesia of the lower extremity and lower abdomen with impaired sphincter control. Although myelitis was ongoing at the time of death (from other cause), symptoms improved with corticosteroids and IV immune globulin.</p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Neurologic toxicities: Neurologic toxicities, which may be severe, life-threatening, or fatal, have occurred with ciltacabtagene autoleucel. Neurologic toxicities included immune effector cell-associated neurotoxicity syndrome (ICANS), neurotoxicity with signs/symptoms of parkinsonism, Guillain-Barr√© syndrome (GBS), peripheral neuropathies, and cranial nerve palsies. Patients should seek immediate medical attention for further assessment and management if signs or symptoms of any of these neurologic toxicities occur at any time (including delayed-onset neurotoxicity). Due to the potential for neurologic events, including altered mental status, seizures, neurocognitive decline, or neuropathy, patients receiving ciltacabtagene autoleucel are at risk for altered/decreased consciousness or coordination in the 8 weeks following ciltacabtagene autoleucel infusion and should refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery during this initial period, and in the event of new onset of any neurologic toxicities.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>ICANS: </i>ICANS, which may be fatal or life-threatening, occurred with ciltacabtagene autoleucel, including before CRS onset, concurrently with CRS, after CRS resolution, or in the absence of CRS; grade 3 or higher ICANS occurred. Common manifestations of ICANS included encephalopathy, aphasia, and headache. The median time to onset of ICANS was 8 days (range: 1 to 28 days). ICANS resolved in over three-fourths of patients; the median time to resolution was 6 days (range: 2 to 143 days), although ICANS symptoms may persist in some patients.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Parkinsonism:</i> Parkinsonism and associated complications, distinct from ICANS, have occurred following treatment with ciltacabtagene autoleucel, including a fatal case. Parkinsonian and nonparkinsonian symptoms included tremor, bradykinesia, involuntary movements, stereotypy, loss of spontaneous movements, masked facies, apathy, flat affect, fatigue, rigidity, psychomotor retardation, micrographia, dysgraphia, apraxia, lethargy, confusion, somnolence, loss of consciousness, delayed reflexes, hyperreflexia, memory loss, difficulty swallowing, bowel incontinence, falls, stooped posture, shuffling gait, muscle weakness/wasting, motor dysfunction, motor and sensory loss, akinetic mutism, and frontal lobe‚Äìrelease signs. The median time to onset of parkinsonism was 64 days (range: 14 to 914 days); symptoms did not respond to multiple treatment lines.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>GBS:</i> GBS and associated complications have occurred, including a case report with a fatal outcome despite treatment with IV immunoglobulin; symptoms included those consistent with Miller-Fisher variant of GBS, encephalopathy, motor weakness, speech disturbances, and polyradiculoneuritis.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Peripheral neuropathy</i>: Some patients developed peripheral neuropathy, which presented as sensory, motor, or sensorimotor neuropathies, including grade 3 events. The median time of symptom onset was 66 days (range: 4 to 914 days) and the median duration was 138 days (range: 2 to 692 days), including those with ongoing neuropathy. In some studies, patients who experienced peripheral neuropathy also experienced cranial nerve palsies or GBS.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cranial nerve palsies</i>: A small number of patients experienced cranial nerve palsies; the median time to onset was 26 days (range: 21 to 101 days); all cases resolved following systemic corticosteroids (¬± valacyclovir) with a median time to resolution of 70 days (range: 1 to 79 days).</p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Secondary malignancies: Patients treated with ciltacabtagene autoleucel may develop secondary malignancies. Myeloid neoplasms (including myelodysplastic syndrome [MDS], acute myeloid leukemia [AML], and MDS followed by AML) have occurred. The median time to the development of myeloid neoplasms was 485 days (range: 162 to 1,040 days). Some cases of myeloid neoplasm occurred following initiation of subsequent antimyeloma treatment. If a secondary malignancy develops, contact the manufacturer (1-800-526-7736) for reporting and to obtain instructions on collection of patient samples for testing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Immunizations: Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during ciltacabtagene autoleucel treatment, and until immune recovery following ciltacabtagene autoleucel treatment. Immunization with live viral vaccines during or following ciltacabtagene autoleucel has not been studied.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Older age: The incidence of neurologic toxicities (all grade and ‚â• grade 3) was higher in patients ‚â•65 years of age, compared to patients &lt;65 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Dimethyl sulfoxide: Ciltacabtagene autoleucel contains DMSO, which is associated with serious hypersensitivity reactions, including anaphylaxis.</p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ Universal precautions: Ciltacabtagene autoleucel contains human blood cells that are genetically modified with replication-incompetent, self-inactivating, lentiviral vector; follow universal precautions and facility biosafety guidelines for handling and disposal to avoid potential transmission of infectious diseases.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">‚Ä¢ REMS program: Ciltacabtagene autoleucel is available only through a restricted program under a risk evaluation and mitigation strategy (REMS) called the CARVYKTI REMS Program. Further information is available at www.carvyktirems.com or 1-844-672-0067.</p></div>
<div class="block foc drugH1Div" id="F56641709"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carvykti: 100000000 CELLS (1 ea)</p></div>
<div class="block geq drugH1Div" id="F56641707"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56695238"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Carvykti Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100000000CELLS (per each): $0.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F56656571"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For IV use only. Administer in a health care facility. Coordinate the timing of administration with thawing. Prime tubing set with NS prior to infusion. Once thawed, administer the entire contents of the bag by IV infusion within 2.5 hours using infusion sets fitted with an in-line filter (do not use a leukodepleting filter). Gently mix the contents of the bag during ciltacabtagene autoleucel infusion to disperse cell clumps. After the entire contents of infusion bag has infused, flush the administration line (including the in-line filter) with a volume of NS ‚â• the total volume capacity of the administration set (including drip tube) to ensure all product is delivered. A central line may be used for administration (and is encouraged in patients with poor peripheral access). Monitor closely for 2 hours after infusion for signs and symptoms of severe hypersensitivity reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">Prior to administration: Ensure tocilizumab (at least 2 doses) and emergency equipment are available prior to infusion and during recovery period. Confirm patient identity and match to patient identifiers on the infusion bag (do not infuse if identifiers do not match). Apply universal precautions for product handling. Premedicate with acetaminophen 650 to 1,000 mg orally and diphenhydramine 25 to 50 mg IV or orally (or other H<sub>1</sub> antihistamine) ~30 to 60 minutes prior to ciltacabtagene autoleucel infusion. Avoid prophylactic dexamethasone or other systemic corticosteroids, as they may interfere with the ciltacabtagene autoleucel activity.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor patient daily (for signs/symptoms of cytokine release syndrome and neurotoxicity) at the health care facility for at least 10 days after cell infusion; monitor periodically for 4 weeks for signs/symptoms of delayed neurotoxicity. Patient should remain within proximity of the facility for at least 4 weeks after infusion.</p></div>
<div class="block meg drugH1Div" id="F56843665"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:2em;">Carvykti: https://www.janssenlabels.com/package-insert/product-patient-information/CARVYKTI-medication-guide.pdf
                  </p></div>
<div class="block use drugH1Div" id="F56628729"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Multiple myeloma, relapsed or refractory:</b> Treatment of relapsed or refractory multiple myeloma in adults after 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.</p></div>
<div class="block mst drugH1Div" id="F56656044"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ciltacabtagene autoleucel may be confused with axicabtagene ciloleucel, betibeglogene autotemcel, brexucabtagene autoleucel, elivaldogene autotemcel, exagamglogene autotemcel, idecabtagene vicleucel, lisocabtagene maraleucel, lovotibeglogene autotemcel, sipuleucel-T, tisagenlecleucel.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F56689870"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F56689867"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within ‚ÄúCYP3A4 Inducers [Strong]‚Äù are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the ‚ÄúLaunch drug interactions program‚Äù link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of CAR-T Cell Immunotherapy. Specifically, the severity and duration of neurologic toxicities may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of CAR-T Cell Immunotherapy. Management: Avoid use of corticosteroids as premedication before treatment with CAR-T cell immunotherapy agents. Corticosteroids are indicated and may be required for treatment of toxicities such as cytokine release syndrome or neurologic toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): CAR-T Cell Immunotherapy may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: The CDC recommends that CAR-T-cell recipients who received COVID-19 vaccine prior to or during treatment with CAR-T-cell therapy should be revaccinated with a primary mRNA vaccine series at least 3 months (12 weeks) after CAR-T-cell therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): CAR-T Cell Immunotherapy may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: The CDC recommends that CAR-T-cell recipients who received COVID-19 vaccine prior to or during treatment with CAR-T-cell therapy should be revaccinated with a primary vaccine series at least 3 months (12 weeks) after CAR-T-cell therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56656075"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to treatment initiation.</p>
<p style="text-indent:0em;margin-top:2em;">Patients were required to use contraception during therapy and for 1 year after the ciltacabtagene autoleucel infusion in clinical studies. Patients who could become pregnant were required to use a highly effective method of contraception. Patients with partners who could become pregnant were required to use a barrier method of contraception.</p></div>
<div class="block pri drugH1Div" id="F56656076"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction and toxicity studies have not been conducted. Based on the mechanism of action, in utero exposure to ciltacabtagene autoleucel<b></b>may cause fetal toxicity, including B-cell lymphocytopenia and hypogammaglobulinemia.</p></div>
<div class="block brc drugH1Div" id="F56656077"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ciltacabtagene autoleucel<b></b>is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F56656573"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Screen for cytomegalovirus, hepatitis B virus (HBV), hepatitis C virus, and HIV or any other infectious agents if clinically indicated in prior to collection of cells (for manufacturing) in accordance with clinical guidelines. Monitor blood counts prior to and after ciltacabtagene autoleucel infusion; monitor hematologic parameters in patients who develop hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Monitor immunoglobulin levels (IgG) after treatment. Consider laboratory testing to monitor for disseminated intravascular coagulation, as well as pulmonary, cardiac, renal, and hepatic function. Verify pregnancy status prior to treatment initiation (in patients who could become pregnant).</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor for cytokine release syndrome (CRS) and signs/symptoms of neurotoxicity during therapy and for at least 4 weeks after infusion. For ‚â• grade 2 CRS, perform continuous cardiac telemetry and pulse oximetry. Monitor patient daily (for signs/symptoms of cytokine release syndrome and neurotoxicity [including immune effector cell-associated neurotoxicity syndrome (ICANS) symptoms]) at the health care facility for at least 10 days after cell infusion; monitor periodically for 4 weeks for signs/symptoms of delayed neurotoxicity. Monitor for neurotoxicity after ciltacabtagene autoleucel treatment; monitor for signs/symptoms of parkinsonism (onset may be delayed), peripheral neuropathy, Guillain-Barr√© syndrome (GBS; patients presenting with peripheral neuropathy should be evaluated for GBS), and cranial nerve palsies. Evaluate for evidence of HLH/MAS in patients with progressive CRS symptoms or refractory CRS despite treatment. Monitor for signs/symptoms of infection (before and after treatment), hepatitis B reactivation, and myelitis. Monitor life-long for secondary malignancies. Monitor closely for 2 hours after infusion for signs/symptoms of severe hypersensitivity reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional neurotoxicity monitoring recommendations (Cohen 2022): In patients with preexisting neurologic disease, consider baseline MRI and EEG and neurologic consultation. Evaluate at the first sign of neurotoxicity, including ICANS and raised intracranial pressure/cerebral edema; assess with new onset of headache, seizure, speech or visual disorders, disturbances in consciousness, confusion, disorientation, coordination/balance/movement disorders, mental status changes, cognitive impairment, and/or personality changes. Evaluate at first sign of neurotoxicity for infectious (eg, human herpes virus), autoimmune, or paraneoplastic/tumoral or metabolic etiologies in blood, cerebrospinal fluid, and/or radiologic imaging. Perform immune effector cell‚Äìassociated encephalopathy assessment tool at baseline and at least daily after first symptoms of neurotoxicity (eg, ICANS or other neurotoxicities) are suspected; continue until resolution. Consider handwriting assessments for early detection of neurotoxicity symptoms. Consider extending neurotoxicity monitoring up to 1 year following ciltacabtagene autoleucel infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology HBV screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]). Obtain baseline ECG, natriuretic peptides, and troponins; a baseline echocardiography is recommended in patients with preexisting cardiovascular disease; consider baseline echocardiography in all patients; for patients who develop ‚â• grade 2 cytokine release syndrome, assess natriuretic peptides and troponins, and obtain echocardiography (ESC [Lyon 2022]). Refer to a cardiologist when clinically indicated.</p></div>
<div class="block pha drugH1Div" id="F56656204"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ciltacabtagene autoleucel is a B cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy in which a patient's T cells are reprogrammed via transduction with a lentiviral vector to express an anti-BCMA chimeric antigen receptor (CAR). The CAR T-cell construct includes an anti-BCMA targeting domain consisting of a CD3-zeta signaling domain and a 4-1BB costimulatory domain. Ciltacabtagene autoleucel is prepared from the patient‚Äôs peripheral blood mononuclear cells (obtained via leukapheresis), which are enriched for T cells. When infused back into the patient, the anti-BCMA CAR T cells recognize and eliminate BCMA-expressing target cells. In addition to T cells, ciltacabtagene autoleucel may contain natural killer (NK) cells.</p></div>
<div class="block phk drugH1Div" id="F56656339"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Ciltacabtagene autoleucel exhibits an initial rapid expansion followed by a rapid decline, and then a slower decline. Patients who received tocilizumab, corticosteroids, or anakinra to manage cytokine release syndrome (CRS) experienced higher ciltacabtagene autoleucel AUC<sub>0 to 28d</sub> and C<sub>max</sub> compared to patients who did not receive tocilizumab, corticosteroids, or anakinra.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: The median time for chimeric antigen receptor transgene levels in peripheral blood to return to predose baseline level was ~100 days postinfusion (range: 28 to 365 days).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributes into bone marrow (from systemic circulation).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Median half-life: ~15 days (range: 3 to ~95 days).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Median time to maximal expansion (in peripheral blood): ~13 days after infusion.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciltacabtagene-autoleucel-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34175021">
<a name="34175021"></a>Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet</i>. 2021;398(10297):314-324. doi:10.1016/S0140-6736(21)00933-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciltacabtagene-autoleucel-drug-information/abstract-text/34175021/pubmed" id="34175021" target="_blank">34175021</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Carvykti (ciltacabtagene autoleucel) [prescribing information]. Horsham, PA: Janssen Biotech Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35210399">
<a name="35210399"></a>Cohen AD, Parekh S, Santomasso BD, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. <i>Blood Cancer J</i>. 2022;12(2):32. doi:10.1038/s41408-022-00629-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciltacabtagene-autoleucel-drug-information/abstract-text/35210399/pubmed" id="35210399" target="_blank">35210399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciltacabtagene-autoleucel-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, L√≥pez-Fern√°ndez T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciltacabtagene-autoleucel-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35658469">
<a name="35658469"></a>Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. <i>J Clin Oncol</i>. 2023;41(6):1265-1274. doi:10.1200/JCO.22.00842<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciltacabtagene-autoleucel-drug-information/abstract-text/35658469/pubmed" id="35658469" target="_blank">35658469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>US Food and Drug Administration (FDA). FDA drug safety communication: FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. <a href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous" target="_blank">https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous</a>. Published November 28, 2023. Accessed December 4, 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciltacabtagene-autoleucel-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 135088 Version 44.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
